Multiple Endpoint Trials Still Need To Limit Primary Endpoints, FDA Advises
This article was originally published in The Pink Sheet Daily
Executive Summary
Soon-to-be-published draft guidance will offer advice to sponsors on co-primary endpoints, composite endpoints, multi-component endpoints and other clinical trial designs.